Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rumor Has It: Can Biogen Find A Buyer For Hemophilia Drugs?

This article was originally published in Scrip

Executive Summary

It's no secret that Biogen Inc. has been facing some issues over the last year as shares have dropped, management has exited and the company has made staffing cuts, but the latest rumors have the big biotech selling off one of its lucrative franchises. The move would not only be a drastic shift for the company, but begs the question: who would buy?

Advertisement

Related Content

Biogen Backs Out Of Hemophilia, But Who Benefits?

Topics

Advertisement
UsernamePublicRestriction

Register

SC065007

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel